Utilize este identificador para referenciar este registo:
http://hdl.handle.net/10362/169886
Título: | Impact of the first year of COVID-19 vaccination strategy in Brazil |
Autor: | Aguilar, Soraida Bastos, Leonardo S.L. Maçaira, Paula Baião, Fernanda Simões, Paulo Cerbino-Neto, José Ranzani, Otavio Hamacher, Silvio Bozza, Fernando A. |
Palavras-chave: | COVID-19 EPIDEMIOLOGY Public health Medicine(all) SDG 3 - Good Health and Well-being |
Data: | 4-Jul-2024 |
Resumo: | Objectives No consensus exists about the best COVID-19 vaccination strategy to be adopted by low-income and middle-income countries. Brazil adopted an age-based calendar strategy to reduce mortality and the burden on the healthcare system. This study evaluates the impact of the vaccination campaign in Brazil on the progression of the reported COVID-19 deaths. Methods This ecological study analyses the dynamic of vaccination coverage and COVID-19 deaths in hospitalised adults (≥20 years) during the first year of the COVID-19 vaccination roll-out (January to December 2021) using nationwide data (DATASUS). We stratified the adult population into 20-49, 50-59, 60-69 and 70+ years. The dynamic effect of the vaccination campaign on mortality rates was estimated by applying a negative binomial regression. The prevented and possible preventable deaths (observed deaths higher than expected) and potential years of life lost (PYLL) for each age group were obtained in a counterfactual analysis. Results During the first year of COVID-19 vaccination, 266 153 517 doses were administered, achieving 91% first-dose coverage. A total of 380 594 deaths were reported, 154 091 (40%) in 70+ years and 136 804 (36%) from 50-59 or 20-49 years. The mortality rates of 70+ decreased by 52% (rate ratio [95% CI]: 0.48 [0.43-0.53]) in 6 months, whereas rates for 20-49 were still increasing due to low coverage (52%). The vaccination roll-out strategy prevented 59 618 deaths, 53 088 (89%) from those aged 70+ years. However, the strategy did not prevent 54 797 deaths, 85% from those under 60 years, being 26 344 (45%) only in 20-49, corresponding to 1 589 271 PYLL, being 1 080 104 PYLL (68%) from those aged 20-49 years. Conclusion The adopted aged-based calendar vaccination strategy initially reduced mortality in the oldest but did not prevent the deaths of the youngest as effectively as compared with the older age group. Countries with a high burden, limited vaccine supply and young populations should consider other factors beyond the age to prioritise who should be vaccinated first. |
Descrição: | Funding Information: This work is part of the Grand Challenges ICODA pilot initiative, delivered by Health Data Research UK and funded by the Bill & Melinda Gates Foundation and the Minderoo Foundation. This study was also supported by the National Council for Scientific and Technological Development (CNPq), the Coordination for the Improvement of Higher Education Personnel (CAPES) - Finance Code 001, Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro (FAPERJ), the Pontifical Catholic University of Rio de Janeiro. OR is funded by a Sara Borrell grant from the Instituto de Salud Carlos III (CD19/00110). PM acknowledges suppor from the CNPq (Grant 311519/2022-9). OR acknowledges support from the Spanish Ministry of Science and Innovation and State Research Agency through the \u2018Centro de Excelencia Severo Ochoa 2019-2023\u2019 programme (CEX2018-000806-S) and support from the Generalitat de Catalunya through the CERCA programme. All authors carried out the research independently of the funding bodies. The findings and conclusions in this manuscript reflect the opinions of the authors alone. Funding Information: SH and FAB are funded by the CNPq and FAPERJ. PM is funded by CNPq (422470/2021-0) and FAPERJ (E-26/211.645/2021 and E-26/201.348/2022). OR is funded by a Sara Borrell fellowship from the Instituto de Salud Carlos III (CD19/00110), acknowledges support from the Spanish Ministry of Science and Innovation and State Research Agency through the \u2018Centro de Excelencia Severo Ochoa 2019\u20132023\u2019 programme (CEX2018-000806-S), support from the Generalitat de Catalunya through the CERCA programme and received a research grant from the Health Effects Institute for research unrelated to this manuscript. OR was also a member of the Data Safety Monitoring Board in the REVOLUTION and STOP-COVID trials, testing treatments against COVID-19, and is currently a member of the Data Safety Monitoring Board of the RENOVATE trial, testing respiratory support strategies in patients with acute respiratory hypoxaemic failure. Publisher Copyright: © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ. |
Peer review: | yes |
URI: | http://hdl.handle.net/10362/169886 |
DOI: | https://doi.org/10.1136/bmjopen-2023-072314 |
ISSN: | 2044-6055 |
Aparece nas colecções: | NMS: CHRC - Artigos em revista internacional com arbitragem científica |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
e072314.full.pdf | 1,58 MB | Adobe PDF | Ver/Abrir |
Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.